Pfizer's sells OTC division to J&J for $16.6B

Clearing the way to focus more on its prescription drug business, Pfizer has agreed to sell its OTC division to Johnson & Johnson for $16.6 billion in cash. The OTC therapies include such market stalwarts as Sudafed and Visine and collectively earned $3.9 billion in revenue last year. J&J also won the OTC rights to Zyrtec when it loses patent protection. Pfizer also said it would buy back up to $17 billion in shares. Shares of Pfizer were buoyed slightly be the news.

- here's the AP report on the sale

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.